HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.

AbstractOBJECTIVE:
The GH receptor antagonist pegvisomant is a highly effective new treatment option in acromegaly. The German Pegvisomant Observational Study (GPOS) was started to monitor long-term safety and efficacy of pegvisomant as prescribed in clinical practice.
DESIGN:
GPOS is an observational, multi-center, surveillance study, which comprises non-interventional data collection.
METHODS:
Of the 229 patients included in the study, 90.4% had previous pituitary surgery, 43.2% were treated by radiation therapy, and 94.3% had previous medical therapy for acromegaly that had been discontinued mainly due to persistent IGF-I elevation or side effects. The intention-to-treat population included 177 patients with at least one post-baseline efficacy measurement.
RESULTS:
IGF-I levels decreased from 1.75+/-0.91-fold the upper limit of normal at baseline to 1.05+/- 0.62 at the 6-month visit, 0.96+/-0.60 at the 12-month visit, and to 0.89+/-0.41-fold after 24 months (P<0.0001). Mean duration of pegvisomant therapy was 51.8+/-35.8 weeks (median=51.9 weeks). IGF-I was normalized in 64.4% at 6 months with a median dose of 15.0 mg/day, in 70.9% at 12 months, and in 76.3% at 24 months. Fasting glucose levels improved from 114.4+/-45.9 to 101.5+/- 42.8 mg/dl after 6 months (P<0.01) and to 100.6+/-33.2 mg/ml after 12 months (P<0.01). General physical condition measured by specific signs and symptoms score improved significantly. Adverse events occurring in >1% were injection site reactions in 7.4%, elevated liver enzymes (>3 times of normal) in 5.2% (3.1% spontaneously normalized during continued treatment), reported increase of pituitary tumor volume in 5.2% (which was verified in 3.1%), and headache in 1.7%.
CONCLUSIONS:
Pegvisomant is generally well tolerated with a safety profile similar to that reported in clinical trials and can effectively reduce IGF-I in patients with acromegaly refractory to conventional therapy.
AuthorsI Schreiber, M Buchfelder, M Droste, K Forssmann, K Mann, B Saller, C J Strasburger,
JournalEuropean journal of endocrinology / European Federation of Endocrine Societies (Eur J Endocrinol) Vol. 156 Issue 1 Pg. 75-82 (Jan 2007) ISSN: 0804-4643 [Print] England
PMID17218728 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Hemoglobin A, Glycosylated
  • Receptors, Somatotropin
  • pegvisomant
  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Glucose
Topics
  • Acromegaly (complications, drug therapy)
  • Adult
  • Aged
  • Female
  • Germany
  • Glucose (metabolism)
  • Hemoglobin A, Glycosylated (metabolism)
  • Human Growth Hormone (adverse effects, analogs & derivatives, therapeutic use)
  • Humans
  • Insulin-Like Growth Factor I (metabolism)
  • Male
  • Middle Aged
  • Receptors, Somatotropin (antagonists & inhibitors)
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: